US precision oncology company Boundless Bio (Nasdaq: BOLD) has announced financial results and business highlights for the ...

A Feature on M&A, VC investment, licensing and partnerships in the radiopharmaceuticals arena.

Oculis Holding (Nasdaq: OCS) reported a net loss of $36 million for the first quarter of 2025, more than double the loss in ...